Clinical trial NCT05692154: A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis
Official title: A Phase IIIb, Single-center, Double-blind, Two-arms, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of 2-day Pre-treatment With Fexofenadine in Patients Suffering From Seasonal Allergic Rhinitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Seasonal Allergic Rhinitis
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2023-01-20
Enrollment: 95
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a proof-of-concept study to demonstrate if a daily dose of a 2-days pre-treatment of Fexofenadine 180mg is effective in alleviating the AR symptoms and to assess the additional benefit to the patient in terms of preventing Allergic Rhinitis (AR) symptoms.

The total study duration per participant is expected at least 4 months, depending on the timing of the screening visit. 5 visits are planned, screening, confirmation inclusion challenge, randomization visit, challenge and end of study visit.

Detailed description: The end of the study is defined as the date of the last visit of the last participant in the study.

A participant is considered to have completed the study if he/she has completed all visits of the study including Visit 5 (Day 5).

Eligibility criteria: Inclusion Criteria:

* Participants are eligible to be included in the study only if all of the following criteria apply:
* Participant is willing to provide written informed consent.
* Adult participants (18 to 80 years old) suffering from seasonal allergic rhinitis (SAR) provoked by Ragweed pollen.
* Participants having a total nasal symptom score (TNSS)-3 ≥4 (with 3 nasal symptoms) at first pollen challenge at Visit 2.
* Having a 2-year history of SAR with Positive skin prick test to Ragweed allergen at screening (with a wheal diameter at least 3 mm larger than that produced by the negative control).

Exclusion Criteria:

* History of anaphylaxis to Ragweed pollen History of asthma or exacerbations in the past 12 months requiring regular inhaled corticosteroids for greater than 4 weeks per year, any oral corticosteroid usage, any emergency department visit for asthma or any asthma-related hospitalization. Mild asthmatics treated only with pro re nata short-acting β2agonists, less than 2 doses per week can be enrolled.
* History of chronic sinusitis, defined as a sinus symptoms lasting greater than 12 weeks that includes 2 or more major factors or 1 major factor and 2 minor factors. Major factors are defined as facial pain or pressure, nasal obstruction or blockage, nasal discharge or purulence or discolored postnasal discharge, purulence in nasal cavity, or impaired or loss of smell. Minor factors are defined as headache, fever, halitosis, fatigue, dental pain, cough, and ear pain, pressure, or fullness.
* History of systemic disease affecting the immune system such as autoimmune diseases, immune complex disease, or immunodeficiency, where, in the opinion of the study physician, participation in the trial would pose a risk or significant effect on the immune system.
* Presence or history of drug hypersensitivity to fexofenadine and/or its excipients.
* Participants unable to stop the following forbidden treatments/nutriments prior to pollen challenge:

  * Antihistamines: within 3 days for first-generation antihistamines, within 2 days for second-generation antihistamines.
  * Intranasal or inhaled corticosteroids: 7 days.
  * Ocular, intranasal, or inhaled sodium cromoglycate: 14 days.
  * High doses of systemic corticosteroids: 30 days.
  * Leukotriene antagonists: 30 days.
  * Intranasal or systemic decongestants: 3 days.
  * Tricyclic antidepressants: 7 days.
  * Any citrus fruits (grapefruit, orange, etc.) or their juices, as well as all fruit juices: 5 days.
  * Aluminum-and-magnesium containing antacids: 7 days.
  * Omalizumab/dupilumab: within 6 months
* Any contraindications to fexofenadine, according to the labeling.
* The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Primary outcomes:
measure: Area Under Curve (AUC) of the Total Nasal Symptoms Score (TNSS-3)
timeFrame: From 0 hour to 6 hours at Day 4
Secondary outcomes:
measure: AUC of Total Ocular Symptoms Score (TOSS) (H0-H6 at Day 4)
timeFrame: From 0 hour to 6 hours at Day 4
measure: AUC of Total Nasal Symptoms Score (TNSS-3) (H0-H12 at Day 4)
timeFrame: From 0 hour to 12 hours at Day 4
measure: AUC of Total Ocular Symptoms Score (TOSS) (H0-H12 at Day 4)
timeFrame: From 0 hour to 12 hours at Day 4
measure: AUC of Total Nasal Symptoms Score (TNSS-3) (Day 1 to Day 4)
timeFrame: From randomization (Day 1) to Day 4
measure: AUC of Total Ocular Symptoms Score (TOSS) (Day 1 to Day 4)
timeFrame: From randomization (Day 1) to Day 4
measure: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
timeFrame: From Day 2 to Day 5
Other outcomes:
Locations:
city: Kingston
country: Canada
facility: Investigational Site Number : 1240001
state: Ontario
Study officials:
affiliation: Sanofi
name: Clinical Sciences & Operations
role: STUDY_DIRECTOR
References: